Clinical Report: A Functional Imaging Strategy Utilizing FDG for Phaeochromocytoma and Paraganglioma Assessment
Overview
This study evaluates the diagnostic performance of FDG PET CT/MRI compared to other imaging modalities for phaeochromocytomas and paragangliomas. FDG demonstrated high detection rates for both primary and metastatic disease among the imaging techniques assessed.
Background
Phaeochromocytomas and paragangliomas (PPGLs) are rare tumors that can secrete catecholamines, leading to significant clinical implications. Accurate imaging is crucial for diagnosis, staging, and management, particularly given the potential for malignancy in paragangliomas. The variability in tumor behavior and biochemical profiles necessitates effective imaging strategies to guide treatment decisions.
Data Highlights
Imaging Modality
Detection Rate
FDG
94.7%
Dotatate
92.1%
mIBG
89.5%
Key Findings
FDG showed a detection rate of 94.7% for PPGLs.
Among patients with metastatic disease, FDG had a 100% detection rate.
FDG SUVmax correlated significantly with plasma 3-methoxytyramine levels (r = 0.56, p = 0.0034).
FDG demonstrated 100% detection in patients with SDHB and VHL mutations.
Triple functional imaging included FDG, Dotatate, and mIBG.
Clinical Implications
The findings indicate the potential role of FDG in functional imaging strategies for PPGLs, particularly in cases with suspected metastatic disease.
Conclusion
FDG PET CT/MRI is an effective imaging modality for the assessment of PPGLs, particularly for metastatic disease.
by Norah Alhazzaa, Mohammad M. R. Eddama, Fawziah Alorfi, Teng Teng Chung, Helen Simpson, Srirangalingam Umasuthan, Steve Hurel, Virginia Rozalen-Garcia, Tom Kurzawinski, Simon Wan, Jamshed Bomanji, Mark Gaze, Tarek Ezzat Abdel-Aziz
